J. Thistlethwaite to Acute Disease
This is a "connection" page, showing publications J. Thistlethwaite has written about Acute Disease.
Connection Strength
0.159
-
Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. The Global Simulect Study Group. Transplantation. 2000 Sep 15; 70(5):784-90.
Score: 0.041
-
Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation. 1999 Sep 15; 68(5):608-16.
Score: 0.038
-
Tacrolimus therapy for refractory acute renal allograft rejection: definition of the histologic response by protocol biopsies. Transplantation. 1996 Oct 15; 62(7):906-10.
Score: 0.031
-
Platelets and capillary injury in acute humoral rejection of renal allografts. Hum Pathol. 2003 Jun; 34(6):533-40.
Score: 0.012
-
Role of STAT4 and STAT6 signaling in allograft rejection and CTLA4-Ig-mediated tolerance. J Immunol. 2000 Nov 15; 165(10):5580-7.
Score: 0.010
-
Drug-induced acute interstitial nephritis in renal allografts: histopathologic features and clinical course in six patients. Am J Kidney Dis. 1999 Sep; 34(3):540-8.
Score: 0.010
-
Tacrolimus therapy for refractory acute renal allograft rejection: a 4-year experience with an aggressive approach. Transplant Proc. 1998 Jun; 30(4):1234-5.
Score: 0.009
-
A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. Transplantation. 1996 Sep 15; 62(5):594-9.
Score: 0.008